letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...5657585960616263646566...100101»
  • ||||||||||  tamoxifen / Generic mfg.
    [VIRTUAL] Association of OPG rs2073618 and aromatase inhibitor induced musculoskeletal symptoms (OnDemand) -  Oct 2, 2020 - Abstract #SABCS2020SABCS_401;    
    Methods : Women with stage 0-III HR+ BC initiating adjuvant endocrine therapy (ET) with tamoxifen or an AI were enrolled in a prospective clinic-based observational cohort...78% received anastrozole, 20% letrozole and 2% exemestane...If confirmed in other cohorts, OPG genotyping may be able to identify individuals with HR+ early BC at increased risk for AIMSS during AI therapy. Alternate ET or interventions to reduce musculoskeletal symptoms may be needed for this population.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    [VIRTUAL] Biomarkers of resistance to palbociclib in ER+ primary breast cancer in the PALLET trial (OnDemand) -  Oct 2, 2020 - Abstract #SABCS2020SABCS_377;    
    PALBO resistance was associated with higher baseline expression of cyclin-E1 (both IHC and RNA), CDK2, and genes related to E2F, MYC, interferon and MTOR signalling. These results suggest that multiple identifiable mechanisms of de novo resistance to PALBO are likely to exist in primary ER+ BC.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) -  Oct 1, 2020   
    P2,  N=40, Recruiting, 
    Progesterone receptor positive tumors may have better response; validation studies are needed. Trial completion date: Jun 2018 --> Jun 2021 | Trial primary completion date: Jan 2018 --> Jan 2021
  • ||||||||||  letrozole / Generic mfg.
    [VIRTUAL] Letrozole associated maculopathy: a rare undesirable effect (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_685;    
    Oestrogen is neuroprotective to the retina and maintains the blood retinal barrier.Both the alpha and beta oestrogen receptor subtypes are expressed and functionally active in RPE, neurosensory retina and choroid. Letrozole, a nonsteroidal aromatase inhibitor possibly breaks the blood retinal barrier by inhibiting the biosynthesis of oestrogen resulting in accumulation of the fluid in the retina.
  • ||||||||||  [VIRTUAL] Macular changes due to aromatase inhibitors (Abstract Channel) -  Sep 28, 2020 - Abstract #EURETINA2020EURETINA_684;    
    Both the alpha and beta oestrogen receptor subtypes are expressed and functionally active in RPE, neurosensory retina and choroid. Letrozole, a nonsteroidal aromatase inhibitor possibly breaks the blood retinal barrier by inhibiting the biosynthesis of oestrogen resulting in accumulation of the fluid in the retina.Aromatase inhibitors associated Maculopathy is a rare side effect and possibly reverses on stopping of them.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Enrollment closed, Enrollment change, Combination therapy:  Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer (clinicaltrials.gov) -  Sep 28, 2020   
    P2,  N=17, Active, not recruiting, 
    Letrozole, a nonsteroidal aromatase inhibitor possibly breaks the blood retinal barrier by inhibiting the biosynthesis of oestrogen resulting in accumulation of the fluid in the retina.Aromatase inhibitors associated Maculopathy is a rare side effect and possibly reverses on stopping of them. Recruiting --> Active, not recruiting | N=46 --> 17
  • ||||||||||  Herceptin (trastuzumab) / Roche, cyclophosphamide intravenous / Generic mfg.
    Clinical, Review, Journal:  HER2-positive pure mucinous breast carcinoma: A case report and literature review. (Pubmed Central) -  Sep 20, 2020   
    It is essential to correctly diagnose the ER(+), PR(-) HER2(+) subtype in mucinous carcinoma. This type should be treated with chemotherapy and anti-HER2 therapy, as well as aromatase inhibitor endocrine therapy.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment change, Trial withdrawal, Metastases:  CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer (clinicaltrials.gov) -  Sep 19, 2020   
    P2,  N=0, Withdrawn, 
    This type should be treated with chemotherapy and anti-HER2 therapy, as well as aromatase inhibitor endocrine therapy. N=204 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  Piqray (alpelisib) / Novartis
    Journal:  Alpelisib to treat breast cancer. (Pubmed Central) -  Sep 18, 2020   
    Although clinical activity has been observed independently of PIK3CA mutation status, clinical improvement has been mostly seen in a higher proportion of patients with PIK3CA-mutated tumors. In this review I share current data on alpelisib in breast cancer treatment.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Effect of rNA interference on Oatp3a1 gene expression on biological characteristics and immune factors of ovarian granulosa cells in rats with PCOS. (Pubmed Central) -  Sep 12, 2020   
    First, rats were intragastrically administered 1 mg/kg letrozole to successfully construct PCOS model...The apoptotic rate was increased obviously (P < 0.05), which was about 2.5 times that of the sham group. This indicates that in the ovarian granulosa cells of rats with PCOS, the interference of Oatp3a1 gene expression can significantly inhibit cell proliferation and promote apoptosis, while inhibiting the expression of immune factors TGF-β1 and VEGF can reduce the expression of NF-κB protein, thereby suppressing the activation of the NF-κB signaling pathway.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Enrollment closed, Enrollment change:  Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) -  Sep 9, 2020   
    P2,  N=24, Active, not recruiting, 
    This indicates that in the ovarian granulosa cells of rats with PCOS, the interference of Oatp3a1 gene expression can significantly inhibit cell proliferation and promote apoptosis, while inhibiting the expression of immune factors TGF-β1 and VEGF can reduce the expression of NF-κB protein, thereby suppressing the activation of the NF-κB signaling pathway. Recruiting --> Active, not recruiting | N=76 --> 24
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    [VIRTUAL] Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) therapy in patients with advanced breast cancer: a single‐centre experience () -  Sep 9, 2020 - Abstract #BAD2020BAD_308;    
    Palbociclib, a cyclin‐dependent kinase 4/6 inhibitor has been shown to improve significantly progression‐free survival in patients with hormone receptor‐positive, human epidermal growth factor receptor 2 (HER2)‐negative, advanced breast cancer, in combination with letrozole (Finn RS, Martin M, Rugo HS et al...N Engl J Med 2016; 375: 1925–36) or fulvestrant (Turner NC, Slamon DJ, Ro J et al...Oral corticosteroids were required in two patients from our cohort, and one patient required hydroxychloroquine...Palbociclib has an increasing role as standard of care in advanced oestrogen‐positive HER2‐negative breast cancer, and it is important for medical oncologists and dermatologists to be aware of its cutaneous adverse effects. Prompt management of adverse effects may limit the negative impact on patients, facilitating beneficial continuation in treatment.
  • ||||||||||  metformin / Generic mfg.
    Journal:  A brief update on the evidence supporting the treatment of infertility in polycystic ovary syndrome. (Pubmed Central) -  Sep 5, 2020   
    Prompt management of adverse effects may limit the negative impact on patients, facilitating beneficial continuation in treatment. This review provides the best available evidence informing recommendations (along with clinical expertise and consumer preference) which provide clinicians with clear advice on best practice for the management of infertile women with PCOS.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    [VIRTUAL] Influence of the CDK4 / 6 inhibitor ribociclib on the peripheral immune response in hormone-receptor-positive breast cancer (Abstract video presentations) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_2178;    
    P3
    We were able to confirm the positive immunomodulatory effects of CDK4/6 inhibitors in regard to the peripheral immune response in the human system, which have been postulated in preclinical studies. The results contribute to future strategies of combination therapies, e.g. CDK4/6 inhibitors in combination with immunomodulatory agents to target the immunosuppressive tumor microenvironment in cancer patients.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    [VIRTUAL] Influence of the CDK4 / 6 inhibitor ribociclib on the peripheral immune response in hormone-receptor-positive breast cancer (Abstract video presentations) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_1464;    
    P3
    We were able to confirm the positive immunomodulatory effects of CDK4/6 inhibitors in regard to the peripheral immune response in the human system, which have been postulated in preclinical studies. The results contribute to future strategies of combination therapies, e.g. CDK4/6 inhibitors in combination with immunomodulatory agents to target the immunosuppressive tumor microenvironment in cancer patients.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    [VIRTUAL] Influence of the CDK4 / 6 inhibitor ribociclib on the peripheral immune response in hormone-receptor-positive breast cancer (Abstract video presentations) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_670;    
    P3
    We were able to confirm the positive immunomodulatory effects of CDK4/6 inhibitors in regard to the peripheral immune response in the human system, which have been postulated in preclinical studies. The results contribute to future strategies of combination therapies, e.g. CDK4/6 inhibitors in combination with immunomodulatory agents to target the immunosuppressive tumor microenvironment in cancer patients.
  • ||||||||||  letrozole / Generic mfg.
    [VIRTUAL] Management of benign metastasizing leiomyoma: a report of three cases () -  Sep 3, 2020 - Abstract #IGCS2020IGCS_612;    
    After administration of letrozole for one month, her back pain improved...Histopathology of CT-guided biopsy was well-differentiated smooth muscle tumors, and she was diagnosed with BML. Because she had no symptoms, she was followed conservatively without treatment.